Menetrier's disease: Long-term remission with lanreotide.
Fiche publication
Date publication
septembre 2015
Auteurs
Membres identifiés du Cancéropôle Est :
Pr CADIOT Guillaume, Pr HOEFFEL Christine
Tous les auteurs :
Heurgue-Berlot A, Feron T, Jazeron JF, Hoeffel C, Diebold MD, Cadiot G
Lien Pubmed
Résumé
Menetrier's disease is a rare hypertrophic gastropathy, causing protein leak. An overexpression of transforming growth factor alpha is involved. In inhibiting the epidermal growth factor receptor, cetuximab and somatostatin analogues are the two most promising treatments, allowing to avoid radical gastrectomy. We report the case of a patient with a sustained clinical remission after treatment with lanreotide, but without complete endoscopic healing. We discuss the available therapeutic options and present a literature review of somatostatin analogues for the treatment of Menetrier's disease.
Référence
Clin Res Hepatol Gastroenterol. 2015 Sep 14. pii: S2210-7401(15)00203-X